Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

"A prerequisite for Orexo to succeed with a sophisticated digital health product like Deprexis is a tight collaboration with ...

Alligator – which has developing mitazalimab on its own after losing Johnson & Johnson as a partner for the drug a few years ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility. The new plant ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the ...

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.